SIC
TRDA icon

SJS Investment Consulting’s Entrada Therapeutics TRDA Stock Holding History

SJS Investment Consulting’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523 Buy
71
+69
+3,450% +$662 ﹤0.01% 2262
2026
Q1 		$26 Buy
+2
New +$23 ﹤0.01% 2347

Other funds holding TRDA

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SJS Investment Consulting's TRDA Position: Q2 2026 in Review

SJS Investment Consulting increased its Entrada Therapeutics (TRDA) stake by 3,450% in Q2 2026, buying an estimated $662 and bringing the position to 71 shares worth $523. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

SJS Investment Consulting first reported a position in TRDA in Q1 2026 and has held it in 2 quarters since. 18 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • SJS Investment Consulting held 71 shares of Entrada Therapeutics worth $523 as of Q2 2026.
  • SJS Investment Consulting bought 69 Entrada Therapeutics shares in Q2 2026, an estimated $662.
  • Entrada Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2262 holding.
  • SJS Investment Consulting first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 18 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.